Profile: OncoMed Pharmaceuticals Inc (OMED.OQ)
23 May 2017
OncoMed Pharmaceuticals, Inc. (OncoMed), incorporated on July 19, 2004, is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Demcizumab (Anti-DLL4, OMP-21M18)
The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Demcizumab has a multi-pronged mechanism of action, including halting cancer stem cell growth and reducing cancer stem cell frequency, disrupting angiogenesis in the tumor, and augmenting anti-tumor immune responses by decreasing monocytic myeloid-derived suppressor cells (MDSCs). The Company is conducting a Phase II trial, known as DENALI, for demcizumab in combination with standard-of-care carboplatin and pemetrexed (Alimta) in non-small cell lung cancer, and a Phase II trial, known as YOSEMITE, for demcizumab in combination with standard-of-care gemcitabine and Abraxane in pancreatic cancer.
Tarextumab (Anti-Notch2/3, OMP-59R5)
Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors. Tarextumab is being evaluated for the treatment of small cell lung cancer. Tarextumab is being tested in the randomized Phase II portion of a Phase Ib/II clinical trial known as PINNACLE in previously untreated patients with extensive-stage small cell lung cancer.
Vantictumab (anti-Fzd7, OMP-18R5)
The Company's vantictumab product candidate is a fully human monoclonal antibody that modulates Wnt pathway signaling by binding to Frizzled receptors one, two, five, seven and eight. The Company has initiated three Phase Ib clinical trials in distinct solid tumor indications in combination with standard-of-care therapies, one trial in each of breast cancer, pancreatic cancer and non-small cell lung cancer (NSCLC).
Ipafricept (Fzd8-Fc, OMP-54F28)
Ipafricept is a Wnt pathway modulator. Ipafricept is a fusion protein, or decoy receptor, containing part of the Frizzled8 receptor (Fzd8) fused to a human Immunoglobulin Fc domain. Ipafricept has shown evidence of anti-tumor activity in solid tumors, including pancreatic, breast, hepatocellular, ovarian, colorectal and other cancers, and reduction of cancer stem cell frequency in multiple preclinical models, either as a single agent or when combined with approved therapies. Ipafricept is in Phase Ib stage of clinical development.
Brontictuzumab (Anti-Notch1, OMP-52M51)
The Company's anti-Notch1 antibody, brontictuzumab, is a humanized monoclonal antibody. It is in Phase Ia of clinical development.
Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83)
Navicixizumab is a monoclonal antibody that targets both DLL4 and vascular endothelial growth factor (VEGF). It has initiated Phase Ib clinical trial for navicixizumab.
Anti-RSPO3 is a monoclonal antibody. Anti-RSPO3 targets the R-spondin (RSPO)-Leucine-rich repeat-containing G-protein coupled receptor (LGR) cancer stem cell pathway. The Company is enrolling patients in a Phase Ia/b clinical trial. The Phase Ia portion of the anti-RSPO3 clinical trial is in solid tumor patients, and the Phase Ib portion of the clinical trial is in colorectal cancer in combination with standard-of-care folinic acid, fluorouracil and irinotecan (FOLFIRI) chemotherapy.
GITRL-Fc trimer (OMP-336B11)
The Company's glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand therapeutic candidate is GITRL-Fc. GITRL-Fc is engineered using a single-gene, linkerless trimer technology that is designed to enable activation of GITR and anti-tumor immune response.
The Company's anti-TIGIT is its antibody that binds to and inhibits T-cell immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) domain protein (TIGIT). The Company's anti-TIGIT therapeutic is intended to activate the immune system through multiple mechanisms and enable anti-tumor activity.
The Company competes with Amgen, AbbVie, Astellas, AstraZeneca, Bayer Pharma AG, Bristol-Myers Squibb, Celgene Corporation, Roche, GlaxoSmithKline LLC, Johnson & Johnson, Lilly, Merck, Merck Serono, Novartis, Pfizer, Regeneron, Sanofi, Stemline Therapeutics, Inc. and Verastem, Inc.
OncoMed Pharmaceuticals Inc
800 Chesapeake Dr
REDWOOD CITY CA 94063-4748
Company Web Links
- BRIEF-Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial
- BRIEF-BVF Partners reports 7.9 pct passive stake in Oncomed Pharmaceuticals as of April 17
- BRIEF-Oncomed reports workforce reduction
- OncoMed's lung cancer drug fails mid-stage study, shares tumble
- UPDATE 2-OncoMed's lung cancer drug fails mid-stage study, shares tumble